A study presented by researchers a the University of California, San Diego, at the American Society of Clinical Oncology’s (ASCO) 2016 annual meeting in Chicago, indicates that precision medicine is moving in a positive direction for multiple cancers, But especially for lung cancer. Currently there have been eight different drivers of tumor growth and there will be more to be evaluated in the future. Trials for new target agents that will amplify medical technologies and treatments are on the horizon. There is hope for cross over application to other cancers and sarcomas . . . for LMS!
Special Note: it is always helpful to know where research is, where it is headed,
In order to stay vigilant for a breakthrough and potential for “cross over” to different cancers and sarcomas . . . .and eventually land on the LMS doorstep.
Knowing as much as you can, allows for better information exchange with your oncology team.